DNLI - Denali Therapeutics - Stock Price & Dividends

Denali Therapeutics Inc. is a biopharmaceutical company that focuses on developing innovative treatments for neurodegenerative diseases and lysosomal storage diseases. The company's primary goal is to create therapies that can effectively cross the blood-brain barrier, which is a significant challenge in treating these types of diseases.

Denali's pipeline includes several promising programs, such as DNL310 ETV, an enzyme replacement therapy for MPS II, a rare genetic disorder. The company is also working on TAK-594/DNL593, a treatment for frontotemporal dementia-granulin, which is currently in Phase 1/II clinical trials. Additionally, Denali has programs targeting MPS IIIA and MPS I, as well as preclinical programs focused on amyloid beta and HER2.

In addition to its transport vehicle-enabled programs, Denali is also developing brain-penetrant small molecule therapies. These include BIIB122/DNL151, a LRRK2 inhibitor program for Parkinson's disease, and SAR443820/DNL788, a RIPK1 inhibitor program for CNS disease. The company is also working on DNL343, an eIF2B activator program for amyotrophic lateral sclerosis, and SAR443122/DNL758, a RIPK1 inhibitor program for peripheral inflammatory diseases.

Denali's early-stage programs include TAK-594/DNL593 for frontotemporal dementia-granulin, DNL126 for MPS IIIA, and DNL622 for MPS I. The company is also exploring its Antibody Transport Vehicle Amyloid beta program and its Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics that aims to address the root cause of diseases by modulating gene expression.

Denali has established collaboration agreements with several major pharmaceutical companies, including Biogen, Genzyme, Takeda, F-star, and Genentech. These partnerships enable the company to leverage the expertise and resources of its partners to accelerate the development of its pipeline.

Denali Therapeutics was founded in 2013 and is headquartered in South San Francisco, California. The company has undergone significant growth and development since its inception, and its commitment to innovation and collaboration has positioned it as a leader in the biopharmaceutical industry.